TABLE 2.

Comparison of Dosing and Titration in Randomized Trials Evaluating Co-Formulations of a Basal Insulin and a GLP-1 Receptor Agonist

DUAL I (34)DUAL IV (40)DUAL VI (41)LixiLan-O (37)
Starting doseIDegLira: 10 unitsIDegLira: 10 unitsIDegLira: 10 unitsiGlarLixi: 10 units
(10 units IDeg + 0.36 mg Lira)(10 units IDeg + 0.36 mg Lira)(10 units IDeg + 0.36 mg Lira)(IGlar 10 units + 5 μg Lixi)
IDeg: 10 unitsPlacebo: same as abovefor both titration schedulesIGlar: 10 units
Lira: 0.6 mg/dayLixi: 10 μg
FPG target (mg/dL)72–9072–10872–9080–100
TitrationIDegLira: twice weekly based on the mean of three consecutive fasting SMBG results; adjustments occurred in 2-unit incrementsIDegLira: twice weekly based on the mean of three consecutive fasting SMBG results; adjustments occurred in 2-unit incrementsIDegLira 1WT: once weekly based on the mean of three consecutive fasting SMBG results; adjustments occurred in 2-unit incrementsiGlarLixi: titration once weekly adding 2 units if FPG was >100 and ≤140 mg/dL or adding 4 units if FPG was >140 mg/dL
IDeg: no limit to titrationPlacebo: same as aboveIDegLira 2WT: twice weekly based on the mean of three consecutive fasting SMBG results; adjustments occurred in 2-unit incrementsIGlar: as above, but dose capped at 60 units
Lira: increased by 0.6 mg weekly to a maximum dose of 1.8 mg/dayLixi: 10 μg for the first 2 weeks, followed by 20 μg thereafter
Mean daily dose at end of trialIDegLira: 39 unitsIDegLira: 28 units41 unitsiGlarLixi: 39.8 units
(39 units IDeg + 1.4 mg Lira)(28 units IDeg + 1.0 mg Lira)(41 units IDeg + 1.48 mg Lira in both arms)IGlar: 40.3 units
IDeg: 62 unitsPlacebo: 44 unitsLixi: not reported
Lira: 1.8 mg
  • 1WT, once weekly titration; 2WT, twice weekly titration; IDeg, insulin degludec U100; IGlar, insulin glargine U100; Lira, liraglutide 6 mg/mL; Lixi, lixisenatide.